Seroatlas · Human Serome Atlas

DBNDD2

Dysbindin domain-containing protein 2

Also known as: C20orf35, DBND2_HUMAN, HSMNP1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9BQY9
Gene: DBNDD2
Ensembl: ENSG00000244274
Chromosome: 20
Canonical length: 259 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm,Cytosol

OverviewNCBI Gene

Predicted to enable ATPase binding activity. Involved in negative regulation of protein kinase activity. Predicted to be located in cytoplasm. Predicted to be active in endoplasmic reticulum and lysosome. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

259 residues, UniProt reviewed canonical sequence.

>Q9BQY9|DBNDD2
     1  MGAGNFLTAL EVPVAALAGA ASDRRASCER VSPPPPLPHF RLPPLPRSRL PGPVSRPEPG
    61  APLLGCWLQW GAPSPGPLCL LFRLCSCTCF APLPAGADMD PNPRAALERQ QLRLRERQKF
   121  FEDILQPETE FVFPLSHLHL ESQRPPIGSI SSMEVNVDTL EQVELIDLGD PDAADVFLPC
   181  EDPPPTPQSS GMDNHLEELS LPVPTSDRTT SRTSSSSSSD SSTNLHSPNP SDDGADTPLA
   241  QSDEEEERGD GGAEPGACS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against DBNDD2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.69
Highest tissue expression: 1,568 nTPM

Expression across tissuesHPA

Tissue

spinal cord: 1,568 nTPM
midbrain: 926 nTPM
hippocampal formation: 722 nTPM
basal ganglia: 567 nTPM
amygdala: 455 nTPM
heart muscle: 441 nTPM

Single-cell type

oligodendrocytes: 619 nCPM
bergmann glia: 135 nCPM
other brain neurons: 34 nCPM
microglia: 33 nCPM
brain excitatory neurons: 25 nCPM
brain inhibitory neurons: 22 nCPM

Immune cell

plasmacytoid DC: 19 nTPM
intermediate monocyte: 13 nTPM
classical monocyte: 10 nTPM
gdT-cell: 9.2 nTPM
memory CD4 T-cell: 8.1 nTPM
myeloid DC: 7.6 nTPM

Brain region

white matter: 1,932 nTPM
basal ganglia: 1,088 nTPM
medulla oblongata: 1,020 nTPM
cerebellum: 916 nTPM
thalamus: 885 nTPM
midbrain: 860 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.96
gnomAD pLI: 0.01
gnomAD missense Z: 0.89
DepMap mean gene effect: 0.15
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 9% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

ATPase binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Phosphoprotein

InteractionsUniProt · HPA

Protein binding partners of DBNDD2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads DBNDD2 as an antibody target. Whether an autoantibody or antibody against DBNDD2 could matter depends on whether native DBNDD2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

DBNDD2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label DBNDD2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...